Abstracts tagged "rheumatoid arthritis"

Abstract Number: 61 • 2017 ACR/ARHP Annual Meeting
Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis
Silvia Hayer¹, Markus Zeilinger^2,3, Volker Weiss^3,4, Markus Seibt⁵, Birgit Niederreiter¹, Tetyana Shvets⁶, Monika Dumanic⁶, Florian Pichler⁶, Marcus Hacker⁶, Josef S. Smolen⁷, Kurt Redlich⁸ and Markus Mitterhauser⁶, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Faulty of Engineering, University of Applied Sciences, Winer Neustadt, Austria, ³Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁴Faculty of Engineering, University of Applied Sciences, Wiener Neustadt, Austria, ⁵Department Internal Medicine III, Division Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria, ⁷Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁸Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: To use in vivo multimodal [18F]FDG (fluoro-D-glucose, tracer for inflammation) and [18F]Sodium Fluoride (bone tracer) positron emission tomography/computed tomography (PET-CT) imaging for the monitoring…
Abstract Number: 2869 • 2017 ACR/ARHP Annual Meeting
Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Katerina Chatzidionysiou¹, Marianne Engström¹, Erik af Klint¹, Aase Hensvold¹ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ) is an anti-IL6R monoclonal antibody approved for the treatment of Rheumatoid Arthritis (RA). There is limited data on synovial tissue histology changes.…
Abstract Number: 171 • 2017 ACR/ARHP Annual Meeting
Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Kamil Slowikowski¹, Hung Nguyen², Gerald Watts², Fumitaka Mizoguchi³, Erika H. Noss⁴, Michael Brenner⁵ and Soumya Raychaudhuri⁶, ¹Harvard University, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁴Division of Rheumatology, University of Washington, Seattle, WA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by immune cell infiltration into the synovial membrane of the joint, where they engage stromal cells such as synovial…
Abstract Number: 2913 • 2017 ACR/ARHP Annual Meeting
the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
Jon T. Giles¹, Jesper Reinholdt², Joan Bathon³, Felipe Andrade⁴ and Maximilian F. Konig⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The oral pathogen Aggregatibacter actinomycetemcomitans (Aa) generates citrullinated proteins targeted by autoantibodies in RA through its pore-forming toxin leukotoxin A (LtxA). Aa-derived LtxA is…
Abstract Number: 394 • 2017 ACR/ARHP Annual Meeting
Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome
Emily Wu¹, Richard Bell², Alex Grier³, Steven Gill⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ³Rochester Genomics Center, University of Rochester, Rochester, NY, ⁴Genomics Research Center, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) has an increased prevalence and severity in women compared to men, yet the underlying etiology of this sexual dimorphism is unknown.…
Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting
Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Bidisha Dasgupta¹, Kristen Sweet¹, Dick DeVries², Benjamin Hsu¹, Ian Gourley¹, Matthew Loza¹ and Peter C. Taylor³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Biologics Europe, Leiden, Netherlands, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
Abstract Number: 395 • 2017 ACR/ARHP Annual Meeting
Pharmacological and Safety Profiles of Cyclin-Dependent Kinase 4/6 Inhibitor, Candidate for Development As Rheumatoid Arthritis Therapeutic Option
Johji Nomura¹, Shunsuke Tsujimoto², Kei Tamura², Wataru Yamamoto², Hiroshi Takahashi², Kyohei Horie², Toshiya Mashiko², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the excessive proliferation of synovial…
Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting
Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis
Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Yoshiya Tanaka¹, Hideto Kameda², Kazuyoshi Saito³, Yuko Kaneko⁴, Eiichi Tanaka⁵, Shinsuke Yasuda⁶, Naoto Tamura⁷, Keishi Fujio⁸, Takao Fujii⁹, Toshihisa Kojima¹⁰, Tatsuhiko Anzai¹¹, Chikuma Hamada¹², Yoshihisa Fujino¹³, Shinya Matsuda¹³ and Hitoshi Kohsaka¹⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ³Tobata General Hospital, Fukuoka, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁷Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, ¹⁰Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ¹¹Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, ¹²Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, ¹³Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
Ruediger Mueller¹, Frederik Mattow², Florian Popp³ and Johannes von Kempis⁴, ¹Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Rorschacherstrasse 95, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 1326 • 2017 ACR/ARHP Annual Meeting
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
Lingshu Zhang^1,2, Pingfang Song², Xiaowei Zhang², Christina Metea², Matthew Schleisman², Lisa Karstens², Eric Leung², Jun Zhang³, Qiang Xu^2,4, Yi Liu⁵, Mark Asquith² and Cong-Qiu Chu^6,7, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²Oregon Health & Science University, Portland, OR, ³MD Anderson Cancer Center, Houston, TX, ⁴Guangzhou University of Chinese Medicine, Guangzhou, China, ⁵Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁶Rheumatology, Oregon Health & Science University, Portland, OR, ⁷Rheumatology, VA Portland Health Care System, Portland, OR
Background/Purpose: Acarbose, an alpha-glucosidase inhibitor anti-diabetic drug exhibited anti-arthritic effects. The mechanism that acarbose exerts its anti-arthritic effects is not fully understood. Since > 90%…
Abstract Number: 1331 • 2017 ACR/ARHP Annual Meeting
A Pathogenic Role of Porphyomonas Gingivalis Fimbriae (FimA) in Periodontitis-Associated Rheumatoid Arthritis
Ji-Won Kim¹, Jennifer Lee², Yeon-Sik Hong³, Sung-Hwan Park² and Ji Hyeon Ju², ¹Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Periodontitis induced by oral pathogen Porphyromonas gingivalis (Pg) has been suggested to be associated with rheumatoid arthritis (RA). Pg peptidyl arginine deiminase -mediated citrullination…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…

1
2
3
…
17
Next Page »